Bone Metastases

Also known as: Bone metastases / Bony secondaries / Bone cancer metastatic / Bony metastases / Osteolytic bone metastases / Metastases to bone / Metastasis to bone / Secondary malignant neoplasm of bone / Secondary malignant neoplasm of bone and bone marrow

DrugDrug NameDrug Description
DB06643DenosumabDenosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and 2 light chains. Each light chain consists of 215 amino acids. Each heavy chain consists of 448 amino acids with 4 intramolecular disulfides. FDA approved on June 1, 2010.
DB00710IbandronateIbandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures.
DB13944Testosterone enanthateTestosterone enanthate is an esterified variant of testosterone that comes as an injectable compound with a slow release rate. It is the first injectable ester preparation of testosterone.[L1158] This slow release is achieved by the presence of the enanthate ester functional group attached to the testosterone molecule.[A31615] This testosterone derivative was developed by Watson pharms Inc and FDA first approved on October 12, 1980. In 2017, about 6.5 million retail prescriptions for testosterone therapy were filled [L4659]. The majority of the prescriptions written were for injectable (66%) and topical (32%) testosterone products. As recent as 1 October 2018, the US FDA approved Antares Pharma Inc.'s Xyosted - a subcutaneous testosterone enanthate product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable autoinjector [L4659]. As the first subcutaneous autoinjector product designed for testosterone replacement therapy, this innovative formulation removes transfer concerns commonly associated with testosterone gels and potentially reduces the need for in-office/in-clinic injection procedures that may inconvenience patients with frequent visits to the clinic [L4659].
DB00399Zoledronic acidZoledronate (zoledronic acid, marketed by Novartis under the trade names Zometa and Reclast) is a bisphosphonate. Zometa is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases. An annual dose of Zoledronate may also prevent recurring fractures in patients with a previous hip fracture. Zoledronate is a single 5 mg infusion for the treatment of Paget's disease of bone. In 2007, the FDA also approved Reclast for the treatment of postmenopausal osteoporosis.
DrugDrug NameTargetType
DB06643DenosumabTumor necrosis factor ligand superfamily member 11target
DB00710IbandronateFarnesyl pyrophosphate synthasetarget
DB13944Testosterone enanthateAndrogen receptortarget
DB13944Testosterone enanthateCytochrome P450 3A4enzyme
DB13944Testosterone enanthateCytochrome P450 19A1enzyme
DB13944Testosterone enanthateAmine oxidase [flavin-containing] Aenzyme
DB13944Testosterone enanthateCholesterol side-chain cleavage enzyme, mitochondrialenzyme
DB13944Testosterone enanthateSerum albumincarrier
DB13944Testosterone enanthateSex hormone-binding globulincarrier
DB13944Testosterone enanthateCytochrome P450 3A5enzyme
DB13944Testosterone enanthateCytochrome P450 3A7enzyme
DB13944Testosterone enanthateSolute carrier organic anion transporter family member 1A2transporter
DB13944Testosterone enanthateSolute carrier family 22 member 8transporter
DB13944Testosterone enanthateSolute carrier family 22 member 7transporter
DB13944Testosterone enanthateMultidrug resistance protein 1transporter
DB13944Testosterone enanthateSodium/bile acid cotransportertransporter
DB13944Testosterone enanthateSolute carrier family 22 member 3transporter
DB13944Testosterone enanthateSolute carrier family 22 member 4transporter
DB13944Testosterone enanthateATP-binding cassette sub-family G member 2transporter
DB13944Testosterone enanthateCytochrome P450 1A1enzyme
DB13944Testosterone enanthateCytochrome P450 1B1enzyme
DB13944Testosterone enanthateCytochrome P450 2A13enzyme
DB13944Testosterone enanthateCytochrome P450 2B6enzyme
DB13944Testosterone enanthateCytochrome P450 2C19enzyme
DB13944Testosterone enanthateCytochrome P450 2C8enzyme
DB13944Testosterone enanthateCytochrome P450 2C9enzyme
DB13944Testosterone enanthateCytochrome P450 3A43enzyme
DB13944Testosterone enanthateEstrogen receptor alphatarget
DB13944Testosterone enanthateMineralocorticoid receptortarget
DB13944Testosterone enanthate3-oxo-5-alpha-steroid 4-dehydrogenaseenzyme
DB00399Zoledronic acidFarnesyl pyrophosphate synthasetarget
DB00399Zoledronic acidGeranylgeranyl pyrophosphate synthasetarget
DB00399Zoledronic acidHydroxylapatitetarget
DB00399Zoledronic acidMultidrug resistance-associated protein 1transporter
DrugDrug NamePhaseStatusCount
DB06724Calcium Carbonate1Not Yet Recruiting1
DB06809Plerixafor1Not Yet Recruiting1
DB00399Zoledronic acid1Completed1
DB00958Carboplatin1 / 2Recruiting1
DB01254Dasatinib1 / 2Active Not Recruiting1
DB01248Docetaxel1 / 2Completed1
DB00997Doxorubicin1 / 2Recruiting1
DB00441Gemcitabine1 / 2Recruiting1
DB01206Lomustine1 / 2Recruiting1
DB01229Paclitaxel1 / 2Recruiting1
DB08913Radium Ra 223 Dichloride1 / 2Active Not Recruiting1
DB09566Radium Ra 223 Dichloride1 / 2Active Not Recruiting1
DB08913Radium Ra 223 Dichloride1 / 2Completed1
DB09566Radium Ra 223 Dichloride1 / 2Completed1
DB00399Zoledronic acid1 / 2Active Not Recruiting1
DB00630Alendronic acid2Terminated1
DB01128Bicalutamide2Active Not Recruiting1
DB01101Capecitabine2Unknown Status1
DB11714Durvalumab2Not Yet Recruiting1
DB08913Radium Ra 223 Dichloride2Completed2
DB06688Sipuleucel-T2Active Not Recruiting1
DB12546Strontium chloride Sr-892Completed1
DB00399Zoledronic acid2Recruiting1
DB00399Zoledronic acid2 / 3Completed1
DB08913Radium Ra 223 Dichloride3Completed1
DB09566Radium Ra 223 Dichloride3Completed1
DB00399Zoledronic acid3Completed4
DB00399Zoledronic acid4Completed1
DB00945Acetylsalicylic acidNot AvailableCompleted1
DB01225EnoxaparinNot AvailableCompleted1
DB08913Radium Ra 223 DichlorideNot AvailableRecruiting1
DB00243RanolazineNot AvailableCompleted1
DB00072TrastuzumabNot AvailableActive Not Recruiting1
DB05773Trastuzumab emtansineNot AvailableActive Not Recruiting1